Zhiqiang Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhiqiang Zhang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Mengyuan Liu
Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang China
2 shared publications- Xinyu Huang
Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang China
2 shared publications - Xu Zhang
Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China
2 shared publications - Chunhong Yu
Department of Hepatobiliary Medicine Fuzong Clinical Medical College of Fujian Medical University Fuzhou China
1 shared publication Chunping Yang
Department of Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang China
1 shared publication- Chunping Yang
Department of Otorhinolaryngology Head and Neck Surgery, the Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang Jiangxi China
1 shared publication
Latest Publications
- 13 April 2026
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1558 (1) , e70258
The Nasal Microbiome in Inflammation and Disease: Bridging Mechanisms to Therapeutics
The nasal microbiome, an integral component of the upper respiratory tract's microecological system, plays a pivotal role in inflammatory diseases such as allergic rhinitis and chronic sinusitis, which affect a substantial population and markedly reduce quality of life. A healthy nasal flora and its metabolites are crucial for maintaining immune homeostasis and mucosal barrier integrity. This review comprehensively discusses the pathological mechanisms, immune interactions, and clinical intervention strategies involving the nasal microbiota in nasal inflammation. It has been shown that dysbiosis of the nasal flora disrupts immune function and compromises the epithelial barrier, thereby initiating and exacerbating a vicious cycle of inflammation. Furthermore, the formation of bacterial biofilms and the emergence of drug resistance contribute to persistent and recurrent symptoms. Regarding treatment, while antibiotics may offer short‐term efficacy, they risk aggravating the microbial imbalance. In contrast, therapies including probiotics, novel immunomodulators, and traditional Chinese medicine demonstrate significant therapeutic potential by restoring microbial balance and modulating immune responses. This review synthesizes current research to provide new perspectives for understanding host–microbiome interactions and to guide future clinical treatments and drug development.
- 13 April 2026
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1558 (1) , e70258
The Nasal Microbiome in Inflammation and Disease: Bridging Mechanisms to Therapeutics
The nasal microbiome, an integral component of the upper respiratory tract's microecological system, plays a pivotal role in inflammatory diseases such as allergic rhinitis and chronic sinusitis, which affect a substantial population and markedly reduce quality of life. A healthy nasal flora and its metabolites are crucial for maintaining immune homeostasis and mucosal barrier integrity. This review comprehensively discusses the pathological mechanisms, immune interactions, and clinical intervention strategies involving the nasal microbiota in nasal inflammation. It has been shown that dysbiosis of the nasal flora disrupts immune function and compromises the epithelial barrier, thereby initiating and exacerbating a vicious cycle of inflammation. Furthermore, the formation of bacterial biofilms and the emergence of drug resistance contribute to persistent and recurrent symptoms. Regarding treatment, while antibiotics may offer short‐term efficacy, they risk aggravating the microbial imbalance. In contrast, therapies including probiotics, novel immunomodulators, and traditional Chinese medicine demonstrate significant therapeutic potential by restoring microbial balance and modulating immune responses. This review synthesizes current research to provide new perspectives for understanding host–microbiome interactions and to guide future clinical treatments and drug development.
- 8 December 2025
- Published by Wiley in Immunology
- Vol. 177 (4) , 749-751
Microplastics in Allergic Rhinitis: Multimechanistic Drivers of Barrier Disruption and Immune Dysregulation
- 8 December 2025
- Published by Wiley in Immunology
- Vol. 177 (4) , 749-751
Microplastics in Allergic Rhinitis: Multimechanistic Drivers of Barrier Disruption and Immune Dysregulation